AUTL AUTOLUS THERAPEUTICS PLC Product Launches 8-K Filing 2024 - FDA Approval Autolus Therapeutics plc announced that the FDA granted marketing approval for AUCATZYL, a treatment for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, on November 8, 2024.Get access to all SEC 8-K filings of the AUTOLUS THERAPEUTICS PLC